Drug intelligence / Profile preview

paclitaxel + trastuzumab + varlitinib

Development stage: Unknown
Lead developer: ASLAN Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

This combination involves **paclitaxel**, a chemotherapy drug used to treat various cancers by inhibiting cell division; **trastuzumab**, a monoclonal antibody targeting HER2-positive breast cancer; and **varlitinib**, a small molecule inhibitor targeting HER1, HER2, and HER4 receptors. The combination is being evaluated for its safety and efficacy in treating HER2-positive metastatic breast cancer.

Targets

EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on paclitaxel + trastuzumab + varlitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + trastuzumab + varlitinib.

Explore the full profile